### Table S1 Point assignments for each variable in the nomogram

| Factors                     | Score |
|-----------------------------|-------|
| **Age (years)**             |       |
| 18–39                       | 0     |
| 40–59                       | 30    |
| ≥60                         | 49    |
| **Race**                    |       |
| White                       | 5     |
| Black                       | 25    |
| Others                      | 0     |
| **Cohabitation status**     |       |
| Non-cohabitation            | 12    |
| Cohabitation                | 0     |
| **Income**                  |       |
| Low                         | 19    |
| High                        | 0     |
| **Tumor size (cm)**         |       |
| 0–2                         | 0     |
| 2–5                         | 6     |
| >5                          | 20    |
| **Lymph node status**       |       |
| No                          | 0     |
| Yes                         | 14    |
| **Tumor grade**             |       |
| Well/moderately differentiated | 0    |
| Poorly/un-differentiated    | 31    |
| **Histotype**               |       |
| IDC                         | 0     |
| ILC                         | 19    |
| Others                      | 16    |
| **Molecular subtype**       |       |
| HR⁺/HER2⁻                   | 0     |
| HR⁻/HER2⁺                   | 14    |
| HR⁻/HER2⁻                   | 23    |
| TN                          | 100   |

### Table S1 (continued)

| Factors                     | Score |
|-----------------------------|-------|
| Brain metastasis            |       |
| Yes                         | 80    |
| No                          | 0     |
| Liver metastasis            |       |
| Yes                         | 39    |
| No                          | 0     |
| Lung metastasis             |       |
| Yes                         | 18    |
| No                          | 0     |
| Chemotherapy                |       |
| No/unknown                  | 36    |
| Yes                         | 0     |

IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; HR, hormone receptor; HER2, human epidermal growth factor receptor-2; TN, triple-negative (HR− HER2−).
Figure S1 Calibration curves for the 3- and 5-year BCSS of the non-surgery group. (A) Internal validation for the 3-year BCSS of the non-surgery group. (B) Internal validation for the 5-year BCSS of the non-surgery group. (C) External validation for the 3-year BCSS of the non-surgery group. (D) External validation for the 5-year BCSS of the non-surgery group. BCSS, breast cancer-specific survival.